

Barclays Wealth Funds

EOS at Federated Hermes

Over the last quarter we made voting recommendations at 1,212 meetings (15,844 resolutions). At 855 meetings we recommended opposing one or more resolutions. We recommended voting with management by exception at 42 meetings and abstaining at four meetings. We supported management on all resolutions at the remaining 311 meetings.

Global

We made voting recommendations at 1,212 meetings (15,844 resolutions) over the last quarter.



- Total meetings in favour 25.7%
- Meetings against (or against AND abstain) 70.5%
- Meetings abstained 0.3%
- Meetings with management by exception 3.5%

Australia & New Zealand


We made voting recommendations at seven meetings (52 resolutions) over the last quarter.



- Meetings against (or against AND abstain) 100.0%

Developed Asia

We made voting recommendations at 127 meetings (1,349 resolutions) over the last quarter.



- Total meetings in favour 43.3%
- Meetings against (or against AND abstain) 55.9%
- Meetings with management by exception 0.8%

Emerging & Developing Markets

We made voting recommendations at 287 meetings (3,125 resolutions) over the last quarter.



- Total meetings in favour 32.8%
- Meetings against (or against AND abstain) 66.2%
- Meetings with management by exception 1.0%

Europe

We made voting recommendations at 164 meetings (2,776 resolutions) over the last quarter.



- Total meetings in favour 25.6%
- Meetings against (or against AND abstain) 70.7%
- Meetings abstained 0.6%
- Meetings with management by exception 3.0%

North America

We made voting recommendations at 465 meetings (5,402 resolutions) over the last quarter.



- Total meetings in favour 10.5%
- Meetings against (or against AND abstain) 83.7%
- Meetings abstained 0.4%
- Meetings with management by exception 5.4%

United Kingdom

We made voting recommendations at 162 meetings (3,140 resolutions) over the last quarter.



- Total meetings in favour 43.8%
- Meetings against (or against AND abstain) 50.6%
- Meetings abstained 0.6%
- Meetings with management by exception 4.9%

The issues on which we recommended voting against management or abstaining on resolutions are shown below.

Global

We recommended voting against or abstaining on 2,473 resolutions over the last quarter.



- Board Structure 48.6%
- Remuneration 24.5%
- Shareholder Resolution 12.4%
- Capital Structure + Dividends 6.1%
- Amend Articles 1.8%
- Audit + Accounts 4.5%
- Investment/M&A 0.4%
- Poison Pill/Anti-Takeover Device 0.1%
- Other 1.7%

Australia & New Zealand


We recommended voting against or abstaining on 20 resolutions over the last quarter.



- Board Structure 40.0%
- Remuneration 50.0%
- Shareholder Resolution 5.0%
- Capital Structure + Dividends 5.0%

Developed Asia

We recommended voting against or abstaining on 204 resolutions over the last quarter.



- Board Structure 80.4%
- Remuneration 3.9%
- Shareholder Resolution 3.4%
- Capital Structure + Dividends 5.9%
- Amend Articles 0.5%
- Audit + Accounts 5.9%

Emerging & Developing Markets

We recommended voting against or abstaining on 730 resolutions over the last quarter.



- Board Structure 48.4%
- Remuneration 12.2%
- Shareholder Resolution 10.3%
- Capital Structure + Dividends 12.2%
- Amend Articles 4.9%
- Audit + Accounts 7.9%
- Investment/M&A 1.2%
- Other 2.9%

Europe

We recommended voting against or abstaining on 355 resolutions over the last quarter.



- Board Structure 31.3%
- Remuneration 39.7%
- Shareholder Resolution 5.4%
- Capital Structure + Dividends 10.4%
- Amend Articles 1.7%
- Audit + Accounts 6.5%
- Poison Pill/Anti-Takeover Device 0.3%
- Other 4.8%

North America

We recommended voting against or abstaining on 991 resolutions over the last quarter.



- Board Structure 51.8%
- Remuneration 25.8%
- Shareholder Resolution 20.5%
- Capital Structure + Dividends 0.2%
- Audit + Accounts 1.5%
- Other 0.2%

United Kingdom

We recommended voting against or abstaining on 173 resolutions over the last quarter.



- Board Structure 30.1%
- Remuneration 58.4%
- Shareholder Resolution 1.2%
- Capital Structure + Dividends 5.8%
- Amend Articles 0.6%
- Audit + Accounts 1.7%
- Poison Pill/Anti-Takeover Device 0.6%
- Other 1.7%